With TX01 and Batten-1, THX Pharma is entering a new strategic phase focused on regulatory approval, early access, and international commercialization of its medicines.
Lyon, France – September 29, 2025, 6 pm CEST – THX Pharma (formerly Theranexus), a pharmaceutical company specializing in rare neurological diseases, today unveils its new corporate and brand identity , marking a new milestone in its development toward the registration and commercialization of its drug candidates for rare neurological diseases.
A Major Milestone in the Company’s Growth Marked by a Name Change
Since its creation, Theranexus has been committed to discovering and developing innovative solutions for patients with rare neurological diseases. By becoming THX Pharma, the company signals its evolution from a biotechnology company to a pharmaceutical company focused on regulatory approvals and market access for its lead drug candidates across multiple geographies.
View the Full Press Release